ArticleJournal of clinical microbiology2004
Characterization of Shiga toxin-producing Escherichia coli strains isolated from human patients in Germany over a 3-year period.
Article in Journal of clinical microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 1 synthesis or guideline pooled it, 374 citations in OpenAlex.
- Estimating the burden of foodborne diseases in Japan.Bulletin of the World Health Organization · 2015Pooled it
- Shiga Toxin-ProducingMicroorganisms · 2025Article
- Genomic Analysis of Antibiotic Resistance and Virulence Profiles inVeterinary sciences · 2025Article
- Article
- Evaluation of the Humoral Response after Immunization with a Chimeric Subunit Vaccine against Shiga Toxin-ProducingVaccines · 2024Article
- Development of a Rapid and Sensitive CANARY Biosensor Assay for the Detection of Shiga Toxin 2 fromToxins · 2024Article
- The diverse landscape of AB5-type toxins.Engineering microbiology · 2023Review
- Cefotaxime-, Ciprofloxacin-, and Extensively Drug-ResistantFoods (Basel, Switzerland) · 2023Article
- Prevalence and Implications of Shiga Toxin-ProducingPathogens (Basel, Switzerland) · 2022Review
- Prevalence and Characterization of Shiga Toxin ProducingMicroorganisms · 2022Article
- Prevalence of Shiga toxin-producing Escherichia coli in Yezo sika deer (Cervus nippon yesoensis) in the Tokachi sub-prefecture of Hokkaido, Japan.The Journal of veterinary medical science · 2022Article
- Risk factors of Shiga toxin-producingEpidemiology and infection · 2022Article
- Identification, Characterization, and Virulence Gene Expression of Marine Enterobacteria in the Upper Gulf of Thailand.Microorganisms · 2022Article
- Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives.Frontiers in cellular and infection microbiology · 2022Review
- Whole-genome characterization of hemolytic uremic syndrome-causing Shiga toxin-producingVirulence · 2021Article
- Virulence determinants and antimicrobial resistance ofSaudi journal of biological sciences · 2021Article
- Diversity of Non-O157 Shiga Toxin-ProducingAnimals : an open access journal from MDPI · 2021Article
- Identification, Shiga toxin subtypes and prevalence of minor serogroups of Shiga toxin-producing Escherichia coli in feedlot cattle feces.Scientific reports · 2021Article
- Comparison of Common Enrichment Broths Used in Diagnostic Laboratories for Shiga Toxin-ProducingMicroorganisms · 2021Article
- Population structure and genetic diversity of non-O157 Shiga toxin-producing Escherichia coli (STEC) clinical isolates from Michigan.Scientific reports · 2021Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have investigated 677 Shiga toxin-producing Escherichia coli (STEC) strains from humans to determine their serotypes, virulence genes, and clinical signs in patients. Six different Shiga toxin types (1, 1c, 2, 2c, 2d, and 2e) were distributed in the STEC strains. Intimin (eae) genes were present in 62.6% of the strains and subtyped into intimins alpha1, beta1, gamma1, epsilon, theta, and eta. Shiga toxin types 1c and 2d were present only in eae-negative STEC strains, and type 2 was significantly (P < 0.001) more frequent in eae-positive STEC strains. Enterohemorrhagic E. coli hemolysin was associated with 96.2% of the eae-positive strains and with 65.2% of the eae-negative strains. Clinical signs in the patients were abdominal pain (8.7%), nonbloody diarrhea (59.2%), bloody diarrhea (14.3%), and hemolytic-uremic syndrome (HUS) (3.5%), and 14.3% of the patients had no signs of gastrointestinal disease or HUS. Infections with eae-positive STEC were significantly (P < 0.001) more frequent in children under 6 years of age than in other age groups, whereas eae-negative STEC infections dominated in adults. The STEC strains were grouped into 74 O:H types by serotyping and by PCR typing of the flagellar (fliC) genes in 221 nonmotile STEC strains. Eleven serotypes (O157:[H7], O26:[H11], O103:H2, O91:[H14], O111:[H8], O145:[H28], O128:H2, O113:[H4], O146:H21, O118:H16, and O76:[H19]) accounted for 69% of all STEC strains. We identified 41 STEC strains belonging to 31 serotypes which had not previously been described as human STEC. Twenty-six of these were positive for intimins alpha1 (one serotype), beta1 (eight serotypes), epsilon (two serotypes), and eta (three serotypes). Our study indicates that different types of STEC strains predominate in infant and adult patients and that new types of STEC strains are present among human isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.